SCHEMBL9719337

SCHEMBL9719337

c1ccc2c(c1)Oc1ccccc1C2Cc1ccncc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP19A1 P11511 3/20 0.43
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
NISCH Q9Y2I1 1/20 0.38
LMNA P02545 5/20 0.37
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ATM Q13315 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736393 0.87 MAOA (0.50) MEN1KMT2AMAOAMAOBLMNA
Hydrochloric Acid SCHEMBL9719431 0.85 MEN1 (0.40) MEN1KMT2AALDH1A1CYP19A1MAOA
SCHEMBL79265 0.85 MAOA (0.48) MEN1KMT2AMAOAMAOBLMNA
SCHEMBL8111113 0.79 CYP19A1 (0.47) CYP19A1MAPTSMN1; SMN2CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL9719344 0.78 CYP19A1 (0.46) CYP19A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL9271782 0.75 CYP19A1 (0.43) CYP19A1LMNAMAPTCYP2D6GAA
SCHEMBL11879292 0.75 MEN1 (0.46) MEN1KMT2AALDH1A1MAOAMAOB
SCHEMBL9389645 0.74 ALOX5 (0.41) MEN1KMT2AALDH1A1LMNACYP1A2
SCHEMBL9269160 0.72 CYP19A1 (0.41) CYP19A1MAOAMAOBCYP1A2CYP3A4
SCHEMBL9266327 0.72 CYP19A1 (0.41) CYP19A1MAOAMAOBCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992000760-A1 METHOD OF TREATING NEUROLOGICAL DYSFUNCTION USING NEUROTRANSMITTER ENHANCES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-01-23 WO disclosed